 |
|
|
| |
C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26
Vienna, Austria
David Roth1, David Nelson2, Annette Bruchfeld3, AnnMarie Liapakis4, Marcelo Silva5, Howard Monsour, Jr6, Paul Martin7, Stanislas Pol8, Maria-Carlota Londoño9, Tarek Hassanein10, Philippe Zamor11, Eli Zuckerman12, Yue Zhao13, Shuyan Wan13, Beth Jackson13, Michael Robertson13, Janice Wahl13, Eliav Barr13, Wayne Greaves13
1Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL; 2Clinical and Translational Science Institute, University of Florida, FL, USA; 3Dept of Renal Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden; 4Yale University Digestive Disease, Yale New Haven Hospital Transplant Center, CT. USA; 5Hospital Universitario Austral, Pilar, Argentina; 6Hepatology & Transplant Medicine, Houston Methodist Hospital, Houston, TX, USA; 7Division of Hepatology, University of Miami Miller School of Medicine, Miami, FL, USA; 8Unité d'Hépatologie, Hôpital Cochin; Université Paris Descartes; UMS20, Institut Pasteur; Paris, France; 9Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd. Spain; 10Southern California Research Center, Coronado, CA, USA; 11Carolinas Medical Center, Charlotte, NC, USA; 12Liver Unit, Carmel Medical Center Technion Faculty of Medicine, Haifa, Israel; 13Merck & Co, Inc. Kenilworth, NJ. USA
|
| |
|
|
|
|
|
